Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 2619 

Hepatitis, STD, and TB Prevention, Centers 

for Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 718– 

8833; Email: GAnderson@cdc.gov. 

The Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, has been delegated the authority 

to sign Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00675 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0001] 

Advisory Committee on Immunization 

Practices 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice and request for comment. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

Advisory Committee on Immunization 

Practices (ACIP). This meeting is open 

to the public. Time will be available for 

public comment. 

DATES: The meeting will be held on 

February 28, 2024, from 8 a.m. to 5 p.m., 

EST and February 29, 2024, from 8 a.m. 

to 3 p.m., EST, (times subject to change; 

see the ACIP website for updates: 

https://www.cdc.gov/vaccines/acip/ 

index.html). 

Written comments must be received 

between February 1–22, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0001, by either of the methods listed 

below. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Ms. Stephanie Thomas, ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2024–0001. 

Instructions: All submissions received 

must include the Agency name and 

docket number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

The meeting will be webcast live via 

the World Wide Web. The webcast link 

can be found on the ACIP website at 

https://www.cdc.gov/vaccines/acip/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee on 

Immunization Practices (ACIP) is 

charged with advising the Director, 

Centers for Disease Control and 

Prevention (CDC), on the use of 

immunizing agents. In addition, under 

42 U.S.C. 1396s, the Committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under applicable provisions of the 

Affordable Care Act and section 2713 of 

the Public Health Service Act, 

immunization recommendations of 

ACIP that have been approved by the 

Director, CDC, and appear on CDC 

immunization schedules generally must 

be covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on influenza 

vaccines, chikungunya vaccine, COVID– 

19 vaccines, meningococcal vaccines, 

pneumococcal vaccines, polio vaccines, 

Human papillomavirus (HPV) vaccines, 

respiratory syncytial virus vaccines, a 

combined Diphtheria and Tetanus 

Toxoids and Acellular Pertussis, 

Inactivated Poliovirus, Haemophilus 

influenzae Type B Conjugate, and 

Hepatitis B vaccine (Vaxelis®), and 

vaccines to prevent diphtheria, tetanus, 

and pertussis. Recommendation votes 

are scheduled for influenza vaccines, 

COVID–19 vaccines, and chikungunya 

vaccine. A Vaccines for Children (VFC) 

vote is scheduled for vaccines to 

prevent diphtheria, tetanus, and 

pertussis. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda, visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/index.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web. For more information on ACIP, 

please visit the ACIP website: https://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near-duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on February 1–22, 2024. 

Written comments must be received by 

February 22, 2024. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes, including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 28–29, 

2024, ACIP meeting must submit a 

request at https://www.cdc.gov/ 

vaccines/acip/meetings/index.html 

between February 1, 2024, and no later 

than 11:59 p.m., EST, February 22, 

2024, according to the instructions 

provided. 


ddrumheller on DSK120RN23PROD with NOTICES1
2620 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by February 26, 2024. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to three minutes, and each 

speaker may speak only once per 

meeting. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00674 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Board of Scientific 

Counselors, National Center for Health 

Statistics 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Board of 

Scientific Counselors, National Center 

for Health Statistics (BSC, NCHS). This 

meeting is open to the public. Time will 

be available for public comment. 

DATES: The meeting will be held on 

March 6, 2024, from 11 a.m. to 5 p.m., 

EST. 

ADDRESSES: Instructions to access the 

live meeting broadcast will be posted 

here: https://www.cdc.gov/nchs/about/ 

bsc/bsc_meetings.htm. 

FOR FURTHER INFORMATION CONTACT: 

Rebecca Hines, M.H.S., Designated 

Federal Officer, Board of Scientific 

Counselors, National Center for Health 

Statistics, Centers for Disease Control 

and Prevention, 3311 Toledo Road, 

Mailstop P–08, Hyattsville, Maryland 

20782. Telephone: (301) 458–4715; 

Email: RSHines@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Board of Scientific 

Counselors, National Center for Health 

Statistics (BSC, NCHS) is charged with 

providing advice and making 

recommendations to the Secretary, 

Department of Health and Human 

Services; the Director, Centers for 

Disease Control and Prevention; and the 

Director, National Center for Health 

Statistics, regarding the scientific and 

technical program goals and objectives, 

strategies, and priorities of NCHS. 

Matters to be Considered: The 

meeting agenda will include an update 

from the NCHS Director; welcoming of 

new Board members; updates from 

NCHS programs; and discussion 

regarding current issues and topics. The 

Board will reserve time for public 

comment at the end of the day. Meeting 

times and agenda topics are subject to 

change as priorities dictate. 

Meeting Information: Please visit the 

BSC, NCHS website for details: https:// 

www.cdc.gov/nchs/about/bsc/bsc_

meetings.htm. Further information and 

the meeting agenda will be available on 

the website, including any agenda 

updates and the instructions for 

accessing the live meeting broadcast. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00641 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–1181; Docket No. CDC–2023– 

0101] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Airline and 

Traveler Information Collection: 

Domestic Manifests and Passenger 

Locator Form. These data collection 

forms align with CDC’s regulatory and 

public health mission under the 

authorities listed in CDC regulations to 

allow CDC to collect passenger and crew 

information from travelers and airlines 

when there has been a confirmed or 

suspected case of communicable disease 

aboard a domestic or international flight 

that puts other travelers at public health 

risk. 

DATES: CDC must receive written 

comments on or before March 18, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0101 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 


ddrumheller on DSK120RN23PROD with NOTICES1